ADial Pharmaceuticals focuses on gene-specific medication to treat addiction and related disorders. The medications target multiple neurotransmitters and brain pathways, which can help change how substance abuse is treated. ADial’s two most advanced compounds specifically target alcohol abuse and dependence.
ADial Pharmaceuticals is a start-up, with headquarters in Charlottesville, Virginia, USA.
Lindéngruppen’s stake in ADial Pharmaceuticals is approximately 13%.
For more information please visit www.adialpharma.com